Global Cardiac Implantable Electronic Device Market, By Type (Implantable Pacemakers And External Pacemakers), By End User (Hospitals, Specialty Clinics, and Ambulatory Care Settings), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 22,576.2 million in 2020 and is expected to exhibit a CAGR 7.7% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
The rapidly evolving COVID-19 pandemic at global level is impacting the cardiac implantable electronic device market negatively. As the hospital outpatient-based cardiac care departments have been placed in the non-essential group by many hospitals, it has become a difficult situation for the patients with cardiac disease.
Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/3949
Rising incidence of cardiovascular diseases such as cardiac arrhythmia, ischemic heart disease, and hypertension is expected to fuel growth of the cardiac implantable electronic device market. According to WHO report, in 2015, cardiovascular diseases was the leading cause of deaths, which accounted for 17.7 million deaths, worldwide.
Furthermore, technological advancements in cardiac management devices is a major factor driving growth of the market. For instance, adoption of advanced technologies in cardiac pacemakers such as pacemakers with improved battery life and MRI safe-pacemakers delay the progression of persistent atrial fibrillation (AF) in patients suffering from bradycardia. These advancements are gaining significant traction and are expected to fuel demand for cardiac rhythm management devices. For instance, in February 2017, Abbott received the U.S Food and Drug Administration (FDA) approval for its MR-conditional labeling for Assurity MRI pacemaker and the Tendril MRI pacing lead.
Browse 26 Market Data Tables and 25 Figures spread through 195 Pages and in-depth TOC on Cardiac Implantable Electronic Device Market, By Type (Implantable Pacemakers And External Pacemakers), By End User (Hospitals, Specialty Clinics, and Ambulatory Care Settings), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Forecast to 2027″
To know the latest trends and insights related to cardiac implantable electronic device market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/cardiac-implantable-electronic-device-market-3218
Major players are adopting strategies such as mergers and acquisitions to expand their product portfolio. For instance, in November 2017, LivaNova PLC and MicroPort Scientific Corporation entered into a binding Letter of Intent (LOI) to sell LivaNova’s Cardiac Rhythm Management (CRM) business franchise to MicroPort for US$ 190 million. The LivaNova PLC Company’s CRM product portfolio includes pacemakers, high-voltage defibrillators, and cardiac resynchronization therapy devices.
Key Takeaways of the Cardiac Implantable Electronic Device Market:
- The cardiac implantable electronic device market is expected to exhibit a CAGR of 7.7% over the forecast period (2020-2027), owing to rising incidence of cardiac disorders
- Among type, the implantable pacemakers segment is expected to hold major revenue share in 2027. The introduction of advanced technologies such as wireless and automated pacemaker and monitoring pacemakers are gaining significant traction among healthcare providers. For instance, in 2016, Biotronik launched CardioMessenger Smart, a portable monitoring device, in the U.S. This system is about the size of a modern smartphone used to keep pacemaker, implantable cardioverter-defibrillator (ICD), and insertable cardiac monitor (ICM) patients connected to their physician remotely. This CardioMessenger Smart helps to ensure patient compliance and consistent transmission of data necessary for physicians to identify and prevent potential cardiac events.
- Major players operating in the cardiac implantable electronic device market include Medtronic plc., Biotronik, Boston Scientific Corporation, Shree Pacetronix Ltd., CCC Medical Devices, Cook Group Incorporated, Braile Biomédica, Abbott Laboratories, Sorin Group, Osypka Medical GmbH, Galix Biomedical Instrumentation Inc., and Oscor Inc.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3949
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027